People: Biogen Idec Inc (BIIB.O)

BIIB.O on Nasdaq

334.39USD
31 Jul 2014
Price Change (% chg)

$-10.13 (-2.94%)
Prev Close
$344.52
Open
$342.72
Day's High
$342.86
Day's Low
$333.35
Volume
1,168,973
Avg. Vol
1,164,513
52-wk High
$358.89
52-wk Low
$203.55

Search Stocks

Scangos, George 

Brief Biography

Dr. George A. Scangos, Ph.D., is Chief Executive Officer, Director of Biogen Idec Inc. From 1996 to July 2010, Dr. Scangos served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University for six years. Dr. Scangos served as non-executive Chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. Dr. Scangos served as the Chair of the California Healthcare Institute in 2010 and was a member of the Board of the Global Alliance for TB Drug Development until 2010. He is also a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America, a member of the Board of Trustees of the Boston Museum of Science and the Biomedical Science Careers Program, and a member of the National Board of Visitors of the University of California, Davis School of Medicine. Dr. Scangos is currently an Adjunct Professor of Biology at Johns Hopkins University. Dr. Scangos has also been appointed to the board of directors of Agilent Technologies, Inc., a provider of bioanalytical and electronic measurement solutions, effective in September 2014.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
5,058,940 -- 760,988 15,015,100

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 1,151,530 14,729,400.00
Name Fiscal Year Total

Stelios Papadopoulos

--

George Scangos

15,015,100

Paul Clancy

4,486,260

Kenneth Di Pietro

3,254,520

Susan Alexander

2,162,200

John Cox

3,671,600
As Of 30 Dec 2013
Search Stocks